Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Japan's Daiichi Sankyo will buy a majority stake in India's top drug maker in a deal that will vault the combined operations into the top 15 pharmaceutical firms globally and end the founding Singh family's role as largest shareholder of Ranbaxy Laboratories
You may also be interested in...
Is Daiichi Sankyo Gearing Up For Arbitration Against Former Ranbaxy Owners?
Daiichi Sankyo continues to believe previous Ranbaxy shareholders concealed information related to U.S. FDA negotiations. Sources say arbitration in Singapore could be taking shape.
Let The Blame Game Begin: Former Ranbaxy Promoter Spars With Daiichi Sankyo
PharmAsia News speaks to former CEO Malvinder Singh and U.S. whistleblower Dinesh Thakur, as the stakes continue to rise in the ongoing saga of India’s Ranbaxy.
A Closer Look: Why Are Indian Pharma Promoters Diversifying Into Other Sectors?
MUMBAI - Earlier this month when Piramal Healthcare Ltd.'s Chairman Ajay Piramal announced a foray into the financial services sector, local pharma watchers were reminded of the much-touted "game-changing" deal that the scion of Ranbaxy Laboratories Ltd. Malvinder Singh struck with Daiichi Sankyo three years ago